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Abstract
Background: Identifying the most appropriate antiretroviral regimen for pregnant women with Human
Immunodeficiency Virus (HIV-1) infection can be challenging, mainly due to pregnancy-related physiological
alterations which can significantly reduce maternal drug plasma concentration. We would like to report our
experience as it consists of an unusual case of low plasmatic concentration of antiretroviral drugs despite
regimen intensification in a HIV-positive pregnant woman. It also underlines the need for accurate monitoring
and treatment adjustment in pregnant women with Human Immunodeficiency Virus (HIV).
Case presentation: A 26-year-old Brazilian woman with HIV-1 infection attending our out-patient clinic
presented with low plasmatic concentration of antiretroviral drugs and persistent detectable viral load despite
regimen intensification during pregnancy.
Trough plasma concentrations of dolutegravir and darunavir were measured by validated liquid chromatography–mass
spectrometry. At 23 weeks of gestation it showed a lower value than expected in non-pregnant adults, compared
to a normal level of plasma concentration measured at 10 weeks after delivery. Our patient and the baby had no
regimen-related adverse effects.
Conclusions: Physiological changes during pregnancy can affect pharmacokinetics and reduce a mother’s bioavailability
of antiretroviral drugs, potentially altering their pharmacological activity. A personalized treatment and a careful follow-up
are hence mandatory for this key population.
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Background
Antiretroviral (ARV) treatment of human immunodefi-
ciency virus (HIV) positive pregnant women has two main
goals: to reduce maternal morbidity and mortality and to
prevent mother-to-child HIV transmission [1]. These ef-
fective drugs have reduced the risk of HIV transmission
from mother to infant to historically low levels both in the
USA and in Europe [2]. The World Health Organization
(WHO) recommends combination antiretroviral therapy
(cART) for all pregnant women disregarding baseline CD4
count or viral load (http://www.who.int/hiv/pub/toolkits/
keypopulations-2016-update/en). However, identifying the
most appropriate regimen for this population can be chal-
lenging. The preferred ARV combination for pregnant
women differs from the ARV combination for the general
HIV-infected adult population, mainly because of altered
pharmacokinetics during pregnancy. Pregnancy can in fact
lead to significant reductions in ARV drugs bioavailability,
particularly during the third trimester [3]. The main
pregnancy-associated physiological alterations are induc-
tion of hepatic drug-metabolizing enzymes and reduced
concentration of plasma proteins due to hemodilution [4].
For most nucleoside/nucleotide reverse transcriptase in-
hibitors and protease inhibitors, a decreased plasma con-
centration during pregnancy due to their metabolism by
the cytochrome P450 3A enzyme family has been demon-
strated [3]. On the other hand, integrase inhibitors follow
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a different metabolic pathway, which involves mainly
UGT1A1, with minor contributions from CYP3A4 [5]. In-
duction of all of these enzymes may lower the bioavailabil-
ity of ARV drugs during pregnancy, as reported by many
authors [6, 7].
In order to minimize the likelihood of vertical trans-
mission of the virus, some authors suggested intensify-
ing the drug regimen during pregnancy by adding
drugs or increasing their daily dose [8, 9], even if the
cost/effectiveness of this strategy remains unclear.
Case presentation
Here we report on a case of low plasmatic concentration
of ARV drugs, with persistent detectable viral load des-
pite regimen intensification, in a pregnant 26-year-old
Brazilian woman with HIV-1 infection.
The first diagnosis of HIV was made in August 2016; at
diagnosis, her CD4 count was 60 cells/mm3 and plasmatic
viral load was 7,060,000 copies/mL. No drug resistance
was reported at the baseline test. She did not report any
alcohol or drug addiction, neither was she under any
medical treatment. She was hence immediately started on
ARV therapy. In accordance with the national Italian
guidelines [10], a cART with abacavir/lamivudine/dolute-
gravir (DTG) (600/300/50mg) once daily was introduced,
which seemed to be well tolerated. Despite a significant
reduction in the viral load (1650, 143, 58 copies/mL after
1, 2, and 4 months respectively), she never achieved
plasmatic undetectability (HIV-ribonucliec acid (RNA)
< 50 copies/mL) at follow-up. When asked, she
reported poor adherence to the therapeutic regimen in
spite of good tolerability.
In February 2017 she got pregnant. She was married
and had adequate social and familial support and thus
decided to go through with her pregnancy. The viral
load at the beginning of pregnancy was 77 copies/mL
with a CD4 count of 219 cells/mm3. After 1 month, the
viral load was lower but still detectable (53 copies/mL).
It was thus decided to implement the ongoing therapy
with darunavir (DRV)-ritonavir (800/100mg) once daily.
Two months later, plasmatic HIV-RNA was 11,400 cop-
ies/mL in a context of reported good adherence. Fur-
thermore, our patient did not report any flu-like illness
or alterations of her general status which could have
contributed to the increase in the viral load. Anticipating
that bioavailability of DTG would be further reduced in
the second and third trimesters, an additional dose of
DTG (50mg) was therefore included in the regimen. At
the following control, 4 weeks later, plasmatic HIV-RNA
was 252 copies/mL.
In order to maximize our patient’s adherence to the
ARV therapy, the frequency of controls was increased to
a monthly basis; when interviewed, she appeared moti-
vated to adhere to the treatment and to follow any
medical advice in order to preserve her health and the
baby’s health. The actual intake of the pills was assessed
by an electronic monitoring system of withdrawn drug
boxes. In addition, at 23 weeks of gestation we collected
a blood sample to determine the effective plasmatic con-
centration of DTG and DRV and to consequently better
document plasmatic levels of ARV drugs. Trough
plasma concentration (Ctrough) was measured by vali-
dated liquid chromatography–mass spectrometry (LC-
MS/MS). For both drugs, analysis revealed a Ctrough of
379 ng/mL (DTG) and 152 ng/mL (DRV), which were
lower than expected in non-pregnant adults [11].
Along with controls at our HIV clinic, our patient
underwent regular gynecologic follow-up. In addition to
HIV infection, the physiology of her pregnancy was con-
sidered. The fetus showed normal growth and no major
abnormalities were detected at ultrasound examinations.
At 34 weeks of gestation, the viral load dropped again
to 81 copies/mL with a CD4 count of 177 cells/mm3; in
accordance with the Italian guidelines [10], a cesarean
section was thus recommended. Two weeks later, our
patient delivered a healthy baby; there were no subse-
quent obstetric complications.
On review at 8 weeks, mother and baby were well; the
baby’s T and B cell numbers were normal, and HIV-RNA
was undetectable. She is thus far uninfected.
Ten weeks after delivery, DTG and DRV concentrations
in maternal blood were again examined. The Ctroughs were
3042 ng/mL (DTG) and 1748 ng/mL (DRV), showing a nor-
mal level of bioavailability for a non-pregnant adult [11].
Our patient’s regimen was then de-intensified to abacavir/
lamivudine/DTG (600/300/50mg) once daily. Her viral
load declined to 38 copies/mL with a CD4 count of 248
cells/mm3 1 month after treatment modification. After an-
other 2 months, her CD4 cell count rose to 398 cells/mm3
and HIV-RNA was < 20 copies/ml.
Discussion and conclusions
Preliminary results from an ongoing observational study
in Botswana aroused some concerns on the use of DTG
during pregnancy, especially at the time of conception
or early in the first trimester, because of an apparent
higher risk for neural tube defects in the infants [12].
Despite a recent warning both from the Food and Drug
Administration (FDA) and the European Medicines
Agency (EMA), a precautionary discouraging of the use
of DTG in pregnancy or in women of childbearing age, a
systematic review on the safety of this drug for pregnant
women showed a risk of adverse birth outcomes and
congenital abnormalities that was similar to results from
historical control studies of HIV-positive women [13].
In our experience, DTG-containing regimens have
always been well tolerated during pregnancy. In addition,
no side effects in mothers or neural tube defects in
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babies born to women using DTG before or during
pregnancy have been reported.
It is, however, true that persistent detectable viral load
together with a low bioavailability of ARV drugs despite
regimen intensification in pregnant women has been
previously described [7]. Furthermore, some authors
already expressed concerns over lower plasmatic con-
centrations of DTG during pregnancy, leading to an in-
crease in the daily dosing [14]. We were also aware of
the potential reduction of DRV concentration during
pregnancy, as it has been shown by several studies of
pharmacokinetics. A 800-mg DRV dose administered
twice daily did not increase DRV exposure in pregnant
women, thus the use of this increased twice daily dose dur-
ing pregnancy is not recommended [9]. On the other hand,
switching to DRV-ritonavir (600/100mg) administered
twice daily could have further compromised adherence.
Physiological changes during pregnancy can affect
pharmacokinetics and reduce bioavailability of ARV
drugs, potentially altering pharmacological activity. This
pharmacological effect has been seen for DTG but also
for other ARVs, with levels of plasmatic concentration
maintained underneath effective levels.
As shown by this case report, plasmatic concentration
of both DTG and DRV were significantly lower during
the second trimester of pregnancy despite the increase
in the daily dosing and reported good adherence. On the
other hand, normal levels of the drugs, in association
with a reduced viral load and a good count of CD4 were
measured 5 weeks after delivery. Our experience con-
firms the need for a careful follow-up and adjustment of
ongoing ARV treatment for pregnant women infected
with HIV-1.
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